Acute Myelogenous Leukemia (AML) - Comprehensive Review

Acute Myelogenous Leukemia (AML) - A Comprehensive Review

1. Introduction

  • Definition: Acute Myelogenous Leukemia (AML), also known as acute myeloid leukemia, acute myeloblastic leukemia, or acute nonlymphocytic leukemia, is a rapidly progressing malignancy of the myeloid lineage of blood cells.
  • Characteristics:
    • Uncontrolled clonal proliferation of immature myeloid precursors called blasts.
    • Occurs in bone marrow, peripheral blood, and occasionally other tissues.
    • Crowding of abnormal blast cells leads to a disruption in the production of functional red blood cells, platelets, and mature white blood cells.
  • Consequences: Results in life-threatening complications including:
    • Anemia
    • Thrombocytopenia
    • Increased susceptibility to infection
  • Prevalence: Most common form of acute leukemia in adults.
  • Prognosis: Historically poor prognosis, especially in older patients, with overall survival rates remaining suboptimal despite advances in molecular genetics.
  • Treatment: Requires prompt diagnosis and aggressive treatment to avoid fatal outcomes.

2. Etiology

  • Multifactorial Nature: Involves genetic predisposition, environmental exposures, and prior hematologic conditions.
  • De Novo vs. Secondary AML:
    • De Novo: Arises without an identifiable predisposing condition.
    • Secondary: Associated with pre-existing hematological disorders or prior cytotoxic therapy.
2.1 Genetic and Chromosomal Factors
  • Chromosomal Abnormalities: Found in approximately 55-60% of AML cases, significantly affecting prognosis and treatment response.
    • Common Abnormalities:
    • t(8;21)(q22;q22): RUNX1 and RUNX1T1 genes fusion.
    • inv(16)(p13.1q22) or t(16;16): CBFB-MYH11 fusion.
    • t(15;17)(q22;q12): Generates the PML-RARA fusion protein, specific to acute promyelocytic leukemia (APL or AML-M3).
  • Gene Mutations: FLT3, NPM1, CEBPA, IDH1, IDH2, DNMT3A, TET2, TP53 mutations.
  • Inherited Syndromes: Conditions enhancing AML risk include:
    • Down syndrome (trisomy 21).
    • Fanconi anemia, Bloom syndrome, Diamond-Blackfan anemia.
    • Li-Fraumeni syndrome (germline TP53 mutations).
2.2 Environmental and Acquired Risk Factors
  • Ionizing Radiation: Strong association, evidenced by increased leukemia rates in Hiroshima and Nagasaki survivors; seen in occupational exposures for nuclear workers and radiologists.
  • Benzene: A potent leukemogen present in cigarette smoke and industrial products; induces DNA damage leading to progression toward AML.
  • Pesticides and Herbicides: Implicated in AML development among agricultural workers.
  • Therapy-related AML (t-AML): Accounts for 10-20% of AML cases; arises from previous cytotoxic therapy.
    • Alkylating agents (cyclophosphamide, melphalan) linked with deletions of chromosomes 5 or 7.
    • Topoisomerase II inhibitors (etoposide, doxorubicin) associated with t-AML with MLL gene translocations.
2.3 Pre-existing Hematologic Conditions
  • Disorders Risk of Transformation to AML:
    • Myelodysplastic syndromes (MDS)
    • Myeloproliferative neoplasms (MPN) - polycythemia vera, essential thrombocythemia.
    • Chronic myeloid leukemia (CML)
    • Aplastic anemia
  • Mechanism: Accumulation of somatic mutations leads to clonal evolution and leukemic transformation.

3. Epidemiology

  • Prevalence: AML constitutes approximately 80% of all acute leukemia diagnoses in adults.
  • Annual Diagnosis: Approximately 20,000-21,000 new cases in the U.S., with 11,000-12,000 deaths per year.
3.1 Age and Sex Distribution
  • Age: Predominantly affects older adults; median diagnosis age is approximately 68 years. Incidence increases with age.
  • Sex: Slight male predominance with a male-to-female ratio of about 1.3:1.
3.2 Racial and Geographic Variation
  • Incidence by Race: Non-Hispanic White individuals exhibit the highest incidence rates; lower rates in Asian/Pacific Islander and Hispanic populations.
  • Outcomes Disparities: Black Americans face worse outcomes than White Americans.
  • Global Trends: Higher incidence in Western Europe, North America, and Australia; underreporting in developing countries.
3.3 Survival Statistics
  • Overall Survival Rate: Approximately 28-30% over 5 years; significantly varies based on age and risk factors.
  • Risk Stratification: Younger patients with favorable-risk cytogenetics can exceed survival rates of 60-70%, while adverse-risk cases may have rates below 10%.

4. Pathophysiology

  • Disruption of Hematopoiesis: Acquired mutations impair normal differentiation of hematopoietic progenitor cells, leading to blast accumulation.
4.1 Two-Hit Model of Leukemogenesis
  • First Hit: Mutations impairing differentiation (e.g., transcription factor mutations).
  • Second Hit: Mutations enhancing proliferation and survival (e.g., FLT3 activating mutations).
4.2 Blast Accumulation and Bone Marrow Failure
  • Blasts Displace Normal Hematopoietic Cells: Resulting in:
    • Anemia from impaired red blood cell production.
    • Thrombocytopenia from impaired platelet production.
    • Neutropenia from impaired mature granulocyte production.
4.3 Molecular Mechanisms
  • Epigenetic Dysregulation: Affecting gene expression favoring self-renewal.
  • Key Mutations:
    • PML-RARA: Fusion protein in APL inhibiting promyelocyte differentiation; sensitive to all-trans retinoic acid (ATRA).
    • FLT3-ITD: Constitutively activates signaling pathways, promotes poor prognosis.

5. Clinical Signs & Symptoms

  • Acute Presentation: Rapidly progressive symptoms primarily due to bone marrow failure.
5.1 Symptoms of Anemia
  • Common Symptoms: Fatigue, weakness, pallor, dyspnea on exertion, palpitations; physical signs include conjunctival and mucosal pallor.
5.2 Symptoms of Thrombocytopenia
  • Bleeding Manifestations: Easy bruising, petechiae, mucosal bleeding, risk of gastrointestinal or intracranial hemorrhage; DIC exacerbates bleeding risk in APL.
5.3 Symptoms of Neutropenia and Infection
  • Functional Neutropenia: Results in susceptibility to infections; fever as most common symptom.
5.4 Leukostasis
  • Complication: High WBC count (typically >100,000/µL) can lead to organ ischemia; requires prompt intervention with hydroxyurea or leukapheresis.
5.5 Other Clinical Features
  • Extramedullary Involvement: Hepatomegaly, splenomegaly, lymphadenopathy, leukemia cutis, gingival hypertrophy.

6. Laboratory Tests & Blood Smear Picture

  • Key Diagnostic Tests:
    • Complete blood count (CBC)
    • Peripheral blood smear
    • Bone marrow examination
    • Cytochemistry
    • Flow cytometry/immunophenotyping
    • Cytogenetics and molecular studies.
6.1 Complete Blood Count (CBC)
  • Abnormal Findings: Normocytic normochromic anemia, thrombocytopenia; WBC count variable.
6.2 Peripheral Blood Smear
  • Characteristic Findings:
    • Myeloblasts: Large immature cells with high N:C ratio and Auer rods (diagnostic for AML).
    • Hypergranular promyelocytes: Seen in APL, with highly coagulable granules.
6.3 Bone Marrow Examination
  • Criteria for Diagnosis: Hypercellularity (>80% cellularity) with blast percentage ≥20%.
6.4 Cytochemistry
  • Cytochemical Stains: Myeloperoxidase (MPO) positivity in myeloblasts; Non-specific esterase for monocytic differentiation.
6.5 Flow Cytometry / Immunophenotyping
  • Myeloid Markers: CD13, CD33, CD117, CD34; APL shows strong CD33 and absence of HLA-DR.
6.6 Cytogenetics and Molecular Studies
  • Chromosomal Analysis: Identify abnormalities and specific gene mutations via PCR and NGS.

7. Treatment & Prognosis

  • Complex and Risk-Adapted Treatment Strategies: Focused on achieving complete remission and preventing relapse.
7.1 Induction Chemotherapy
  • Standard Regimen: "7+3" - cytarabine (ara-C) and anthracycline (daunorubicin or idarubicin); achieves CR in 60-80% of younger, 40-60% of older patients.
7.2 Targeted Therapies
  • New Advances: FLT3 inhibitors midostaurin and gilteritinib; IDH inhibitors enasidenib and ivosidenib; BCL-2 inhibitor venetoclax combined with hypomethylating agents.
7.3 Treatment of APL (AML-M3)
  • Effective Treatment: ATRA and arsenic trioxide yield >90% cure rates in low-risk patients without chemotherapy; prompt recognition necessary due to DIC complications.
7.4 Consolidation and Stem Cell Transplantation
  • Post-Remission Strategies: Consolidation therapy (high-dose cytarabine) and allo-HSCT for intermediate/adverse risk patients.
7.5 Prognosis
  • Factors Influencing Prognosis: Age, performance status, comorbidities, disease biology (cytogenetics and molecular mutations).
  • Risk Stratification: Favorable-risk AML shows 5-year survival of 50-65%; adverse-risk AML shows median survival below 12 months.
  • Importance of MRD Assessment: Monitoring residual leukemic cells to guide treatment decisions and improve outcomes.